Inexpensive drug appears to relieve fibromyalgia pain
April 17, 2009 by admin · Leave a Comment
For Tara Campbell, the onset of her fibromyalgia began slowly with repeated sore throats, fevers and fatigue. By the time she was diagnosed, a year later, she had become so debilitated by flulike symptoms and exhaustion that she often couldn’t get off the couch all day.
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
February 14, 2009 by admin · Leave a Comment
First new treatment option in more than 40 years, marking second FDA approval for Takeda within one month
DEERFIELD, Ill., and OSAKA, Japan, Feb. 13 /PRNewswire/ — Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the United States Food and Drug Administration (FDA) has approved ULORIC(R) (febuxostat) 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. This once-daily, oral medication is the first new treatment option in more than 40 years for the more than five million patients who have hyperuricemia associated with gout. ULORIC was discovered by Teijin Pharma Limited (Teijin Pharma) of Tokyo and licensed to Takeda for the U.S. market.
Fibromyalgia no longer an ‘invisible’ syndrome
November 4, 2008 by admin · Leave a Comment
Molecular imaging uncovers evidence that symptoms are related to functional brain abnormalities, according to article in the Journal of Nuclear Medicine
A major step toward a more targeted treatment for auto-immune diseases?
January 28, 2008 by admin · Leave a Comment
More and more people in Western society are suffering from auto-immune diseases. Discovering the cause of these chronic inflammations is a first important step in the search for targeted medicines. VIB researchers connected to Ghent University and the Katholieke Universiteit Leuven joined forces and have elucidated the function of MALT1, a key player in controlling inflammatory reactions. They are the first to show that MALT1 is able to cleave the A20 protein, which inhibits inflammation. Scientists hope that by counteracting MALT1 they will be able to restore the body’s natural inhibition of inflammation and thus provide an alternative for treatments that tax the immune system. This would represent a profound improvement over current medicines. Their research will be published in the authoritative journal Nature Immunology.
Why don’t painkillers work for people with fibromyalgia?
September 27, 2007 by admin · 4 Comments
Research may explain why common drugs don’t help
ANN ARBOR, Mich. — People who have the common chronic pain condition fibromyalgia often report that they don’t respond to the types of medication that relieve other people’s pain. New research from the University of Michigan Health System helps to explain why that might be: Patients with fibromyalgia were found to have reduced binding ability of a type of receptor in the brain that is the target of opioid painkiller drugs such as morphine.
Chronic fatigue syndrome linked to stomach virus
September 13, 2007 by admin · Leave a Comment
Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach
Chronic fatigue syndrome, also known as ME (myalgic encephalitis), is linked to a stomach virus, suggests research published ahead of print in Journal of Clinical Pathology.
Live Chat Q&A with Chronic Fatigue Syndrome Research & Policy Leader Leonard A. Jason, PhD
Welcome to our Live Chat Event with Dr. Leonard A. Jason, PhD - a clinical & community psychologist, and a prolific ME-CFS researcher.
As head of the Center for Community Research at DePaul University since 2000, Dr. Jason has several different ME-CFS studies going on at any one time. Community-based research is his specialty, with a focus on defining “the true face” of CFS and other ‘controversial’ illnesses.
Next Step in Study of Valganciclovir for Treatment of Chronic Fatigue Syndrome Recruiting at Stanford
July 20, 2007 by admin · Leave a Comment
Professor Jose G. Montoya, MD, is now recruiting subjects for the next phase in his studies of the antiviral drug valganciclovir (ValcyteTM) in “Chronic Fatigue Syndrome patients who have elevated antibody titers against Human Herpes Virus 6 (HHV-6) and Epstein-barr Virus and are experiencing long-standing fatigue and cognitive impairment.”
